P&T Perspectives

Real P&T Professionals. Real Market Research.

Exposing potential obstacles through market research with unbiased and objective insights from P&T decision-makers is critical.

MMIT P&T Perspectives provides qualitative and tangible feedback through a realistic simulated P&T session that informs your individual brand strategy and enables you to understand how your product and/or competitor’s product will fare in an actual P&T Committee review.

Learn More

Predict

Predict how a P&T Committee might evaluate your drug against competitors.

Understand

Understand how pricing could impact your drug’s placement on formulary.

Identify

Identify the types of coverage restrictions that could be placed on your therapy and competitors.

Improve

Improve your drug’s launch trajectory by identifying the most competitive contracting scenarios.

Features

How We Help

MMIT's industry-leading P&T panel consists of pharmacy decision-makers at health plans, PBMs, providers and integrated delivery systems. 100% of panelists are either active P&T participants or control access for pharmaceuticals for their organizations, giving you unparalleled visibility into these entities.

Simulate

Simulate a typical payer or IDN P&T committee, including a pharmacy director, medical director, contracting executives, and physicians and disease state specialists.

Analyze

Analyze a clinical dossier developed autonomously by a clinical pharmacist, with the opportunity to provide additional clinical data and/or target product profile.

Observe

Observe a 90 minute live-streamed session, including a 45 minute clinical overview and discussion based on the clinical dossier and a 45 minute financial overview and discussion led by the contracting pharmacist.

Question

Ask specific questions of the double-blinded participants during a 15-minute Q&A session after the P&T meeting concludes.

View Samples of Recent P&T Sessions

Showcase 1

Showcase 1

Slide 1

Discover More About P&T Perspectives

DOWNLOAD NOW

Slide 3

Additional Resources

Use Case

Syndicated P&T Session

A pharma company with several approved brands with large market share was developing a new Crohn’s disease drug. The company partnered with MMIT to determine whether the new drug would be approved in the marketplace.

DOWNLOAD

Case Study

Preparing for Launch with P&T Perspectives

Learn how a P&T review helped one pharma company understand how its product would be assessed, leading to a new focus on gathering real-world evidence.

DOWNLOAD

Webinar Recording

Understanding the Impact of Humira Biosimilars on Market Access

Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.

VIEW

Related Solutions to Support Your Strategy

Message Monitor

Solution

Message Monitor

Use Message Monitor to capture key payer and IDN decision-makers’ insights around brand perception so you can better position your product against the competition.

LEARN MORE

mature-businesswoman-using-computer-at-desk

Strategic Launch Report

Solution

Strategic Launch Report

MMIT launch reports help manufacturers vet potential analog products, outline payer and channel segmentation, and highlight potential restrictions to drug launch policies, speeding up commercialization.

LEARN MORE

businesswoman-using-a-digital-tablet-with-graphs-on-it

Rapid Response

Solution

Rapid Response

Improve your brand strategy with Rapid Response’s quick, actionable answers to key business questions among a representative sample of the payer and IDN stakeholders that you care about.

LEARN MORE

group-of-corporate-businesspeople-working-in-the-boardroom

Analytics

Solution

Analytics

As the leading platform for pharma market access teams, MMIT Analytics analyzes comprehensive formulary, policy and restriction information to evaluate patient access for your brands, competitors and analogs.

LEARN MORE